# Navidea sells North American Lymphoseek rights to Cardinal Health in $310M deal

Navidea Biopharmaceuticals signed a definitive asset purchase agreement with Cardinal Health for its Lymphoseek product. Navidea will receive $80 million at closing plus up to $230 million in milestone payments through 2026, with over $20 million guaranteed over the next 3 years.

- Type: Acquisition
- Announced: 2016-11-28
- Where: United States
- Value: $310.0M
- Status: announced
- Products: Lymphoseek (lymphatic mapping and lymph node biopsy product)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Navidea Biopharmaceuticals](https://endata.com/companies/20233.md)
- [Cardinal Health](https://endata.com/companies/20234.md) (acquirer)

## Sources

- [drugdeliverybusiness.com](https://www.drugdeliverybusiness.com/navidea-deals-na-lymphoseek-rights-cardinal-health-310m-deal/), 2016-11-28: "Navidea Biopharmaceuticals said today that it inked a definitive asset purchase agreement with Cardinal Health for its Lymphoseek product."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.